•  
  •  
  •  
 

RNA Leaders

We focus on developing novel RNA-centered approaches to addressing unmet medical needs. SomaGenics' research and development has been supported by over $20M in competitive grants and it is our policy to publish the results of our efforts in respected peer-reviewed journals. Our staff includes internationally recognized leaders in RNA research and technology development. Learn more...

more about SomaGenics

Latest from SomaGenics

 

SomaGenics awarded NIH funding to develop novel cell-free-DNA liquid biopsy platform

Santa Cruz, CA, May 2017- SomaGenics announced the receipt of a Phase I SBIR grant from the National Human Genome Research Institute to support extension of its RealSeq® platform to...

Read more

SomaGenics Presents RNAi Therapeutic Program

Santa Cruz, CA, May, 2017 – SomaGenics’ President and CEO, Brian Johnston, Ph.D., recently presented an invited seminar, “Treating chronic diabetic wounds: A small RNA approach,” to the Institute for...

Read more

SomaGenics presented research progress at the Symposium on Advanced Wound Care and Wound Healing Society

Santa Cruz, CA, April 2017 – SomaGenics presented recent progress in its wound healing therapeutic program at the joint meeting of the Symposium on Advanced Wound Care and the Wound...

Read more

SomaGenics is a privately held biotech company with offices and laboratories located in Santa Cruz, CA. We specialize in small RNA technologies, including innovative RNAi-based therapeutics using sshRNA molecules, and diagnostics/biomarker detection of small or fragmented RNA, including microRNAs.

learn more